Page 205 - Read Online

Table 5: Some siRNAs designed against GFR genes for treating cancer. The vehicles to carry these siRNAs,
their functionality in tumor progression and the experimented cell lines are listed
Targeted genes Delivery vehicle Functionality in tumor Cell/animal models References
progression
EGFRvII (encapsulated Cyclodextrin-modifi ed dendritic Decreases cell proliferation, Brain cancer cells [55]
with Erlotinib or SAHA) polyamines (DexAMs) induces apoptosis (U78 glioblastoma)
(cationic biodegradable
polymer)
ErbB2 (encapsulated Carbonate apatite nanoparticles Decreases cell viability, 4T1 cells induced breast [56]
with wild p53 gene) (inorganic pH sensitive) delays tumor growth cancer mouse
ErbB2 Folate linked lipid-based Inhibits tumor growth KB (cervical [57]
nanoparticles adenocarcinoma-
(cationic liposome) overexpresses folate
receptors) cells induced
nasopharyngeal cancer mouse
IGFR1R (encapsulated Carbonate apatite nanoparticles Inhibits cellular growth/ 4T1 cells induced breast [58]
with wild p53 gene and (inorganic pH sensitive) proliferation, regresses tumor cancer mouse
anti Bcl-2 siRNA) growth, enhances drugs’
sensitivity
IGF1R Lipofectamine 2000 Lowers cell proliferation. Liver cell lines [59]
(cationic liposome) increases sensitivity of (HepG2 and Huh7 cells)
drug (adriamycin), induces
apoptosis
PDGFRα siLentFect (cationic liposome) Sensitizes cells to AKI Pancreatic cancer cells [60]
treatment
FGFR1 Lipofectamine/oligofectamine Reduces cell viability, Breast cancer cells [61,62]
(cationic liposome) increases sensitivity of cells (MDA-MB-134)
to drug (4-hydroxytamoxifen)
EGFR1, IGF1R Lipofectamine Induces cell death, increases Liver cell lines (Huh7 cells [63]
sensitivity of adriamycin with mutated p53 gene)
GFR: Growth factor receptor; SAHA: Suberoylanilide hydroxamic acid; AKI: Aurora kinase inhibitor; siRNA: Short interfering RNA

Financial support and sponsorship 1983;80:1228-31.
8. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M,
The work was supported by a research grant Collins C, Henzel W, Le Bon T, Kathuria S, Chen E.
(FRGS/2/2013/SG05/MUSM/02/2) of the Ministry of Insulin-like growth factor I receptor primary structure:
Higher Education (MOHE), Malaysia. comparison with insulin receptor suggests structural
determinants that defi ne functional specifi city. EMBO J
Confl icts of interest 1986;5:2503-12.
There are no confl icts of interest. 9. Kaleko M, Rutter WJ, Miller AD. Overexpression of
the human insulinlike growth factor I receptor promotes
References ligand-dependent neoplastic transformation. Mol Cell Biol
1990;10:464-73.
1. Witsch E, Sela M, Yarden Y. Roles for growth factors in 10. Valentinis B, Baserga R. IGF-I receptor signalling in
cancer progression. Physiology (Bethesda) 2010;25:85-101. transformation and differentiation. Mol Pathol 2001;54:133-7.
2. Elliott RL, Blobe GC. Role of transforming growth factor 11. Prager D, Li HL, Asa S, Melmed S. Dominant negative
Beta in human cancer. J Clin Oncol 2005;23:2078-93. inhibition of tumorigenesis in vivo by human insulin-like
3. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat growth factor I receptor mutant. Proc Natl Acad Sci U S A
Rev Cancer 2013;13:871-82. 1994;91:2181-5.
4. Demoulin JB, Essaghir A. PDGF receptor signaling networks 12. Kong FM, Anscher MS, Washington MK, Killian JK,
in normal and cancer cells. Cytokine Growth Factor Rev Jirtle RL. M6P/IGF2R is mutated in squamous cell carcinoma
2014;25:273-83. of the lung. Oncogene 2000;19:1572-8.
5. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth 13. Oka Y, Waterland RA, Killian JK, Nolan CM, Jang HS,
factor receptor inhibitors as a cancer treatment: from a Tohara K, Sakaguchi S, Yao T, Iwashita A, Yata Y, Takahara T,
biologic rationale to medical perspectives. Cancer Discov Sato S, Suzuki K, Masuda T, Jirtle RL. M6P/IGF2R tumor
2013;3:264-79. suppressor gene mutated in hepatocellular carcinomas in
6. Pilch PF, Czech MP. The subunit structure of the high affi nity Japan. Hepatology 2002;35:1153-63.
insulin receptor. Evidence for a disulfi de-linked receptor 14. Lücke CD, Philpott A, Metcalfe JC, Thompson AM,
complex in fat cell and liver plasma membranes. J Biol Chem Hughes-Davies L, Kemp PR, Hesketh R. Inhibiting mutations
1980;255:1722-31. in the transforming growth factor beta type 2 receptor in
7. Jacobs S, Kull FC Jr, Cuatrecasas P. Monensin blocks the recurrent human breast cancer. Cancer Res 2001;61:482-5.
maturation of receptors for insulin and somatomedin C: 15. Kim WS, Park C, Jung YS, Kim HS, Han J, Park CH, Kim K,
identifi cation of receptor precursors. Proc Natl Acad Sci U S A Kim J, Shim YM, Park K. Reduced transforming growth
198 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦